PlusLife Biotech

What PlusLife Biotech does

PlusLife Biotech (Guangzhou Pluslife Biotechnology Co., Ltd.) is a privately-held molecular diagnostics company founded in 2017 and headquartered in Guangzhou, China, with a regional office in Hong Kong. The company develops point-of-care nucleic acid testing instruments and consumables built on its proprietary RHAM (RNase Hybridization Assisted Amplification) isothermal amplification platform, which delivers PCR-comparable sensitivity without cold-chain logistics or laboratory infrastructure. Its hardware lineup centres on the palm-sized MiniDock device and the eight-channel Dock Pro 8 benchtop instrument, supported by a menu of more than sixteen test cards spanning tuberculosis (MiniDock MTB Test), respiratory infections (SARS-CoV-2, influenza A/B, RSV, Mycoplasma pneumoniae, Strep A), sexually transmitted infections (HPV 16/18/45, TV/MG, GBS), and monkeypox. Manufacturing, R&D, and offices are consolidated in a 10,000+ square-metre Guangzhou facility, with ISO 13485 certification in place since 2021.

The company operates a razor-and-blade revenue model anchored on instrument placement and recurring consumable (test card) sales. Per-test cartridge pricing for the MiniDock MTB Test is approximately USD 3.60 with devices priced near USD 300, positioned as up to 90% cheaper than incumbent molecular platforms. Go-to-market is centred on institutional public-health procurement: the MiniDock MTB Test is the first product endorsed under the World Health Organization's newly established NPOC molecular TB diagnostic category (March 2026) and is the anchor of the Global Fund to Fight AIDS, Tuberculosis and Malaria's 13-country Early Adopter initiative, supported by USD 50 million from the Children's Investment Fund Foundation and additional Stop TB Partnership TB REACH Wave 11 Plus backing. Beyond public-sector TB programmes, PlusLife sells into clinical and outreach settings and operates an adjacent veterinary diagnostics line (PluslifeVet).

Across disclosed funding rounds PlusLife has raised approximately RMB 250 million in equity — a 2021 Series A (RMB 100M led by Qiming Venture Partners), a 2022 Series A+ (RMB 50M led by Qiming Venture Partners), and a 2025 Series B (RMB ~100M led by FC Innovation Venture Fund and Guoju Venture Capital, with Puhua Capital and Qiming Venture Partners) — supplemented by Gates Foundation grant funding for WHO prequalification work and manufacturing capacity. Founder Prof. Sunny Songyang serves as Chief Scientist, and WHO prequalification for the TB test remains in progress with Gates Foundation support.

Name

PlusLife Biotech

Legal name

Guangzhou Pluslife Biotechnology Co., Ltd.

Website

https://pluslife.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

101–250 employees

Short description

PlusLife Biotech is a Chinese molecular diagnostics company that builds portable and benchtop isothermal amplification devices (MiniDock, Dock Pro 8) on its proprietary RHAM platform, with a sixteen-plus test-card menu spanning tuberculosis, respiratory infections, STIs, and emerging pathogens, serving primarily national TB programs and global health initiatives in high-burden, resource-limited countries.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics (In Vitro Diagnostics)

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Tuberculosis & Mycobacterial Diseases (HLAKAGAH)

akta.pro secondary industry

Microbiology & Infectious Disease Testing (Trial Support) (HLAGAEAF)

Keywords

• Molecular diagnostics
• Point-of-care testing
• Isothermal amplification
• Tuberculosis diagnostics
• Infectious disease detection

Headquarters

HQ city

Guangzhou

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic Devices and Test Cards: PlusLife generates revenue through sale of diagnostic instruments (MiniDock, Dock Pro 8) and associated test cards for infectious diseases including TB, respiratory infections, and STIs. Devices provide recurring test card revenue through compatible test menus (16+ tests compatible with Dock Pro 8).
2. MiniDock MTB Test (TB Diagnostic): Battery-operated near point-of-care TB test priced at $3-4 per test (approximately $3.60 per cartridge). Device costs approximately $300. Tests delivered at decentralized testing settings enabling recurring revenue from national TB programs.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

PlusLife Biotech develops and manufactures molecular point-of-care diagnostic devices (MiniDock portable and Dock Pro 8 benchtop) and a menu of single-use test cards built on its proprietary RHAM isothermal nucleic acid amplification technology. The company sells these products primarily to national TB programs, ministries of health, and primary healthcare facilities in high-burden low- and middle-income countries for decentralized infectious disease diagnosis, with tuberculosis as the flagship indication.

Product overview

Pluslife Biotech offers a molecular point-of-care testing ecosystem centered on RHAM (RNase Hybridization Assisted Amplification) isothermal amplification technology. The portfolio consists of two core diagnostic devices—MiniDock (portable, palm-sized) and Dock Pro 8 (8-channel benchtop system)—complemented by over 16 test cards covering infectious diseases with heavy burdens (including MiniDock MTB Test for tuberculosis), respiratory infections (SARS-CoV-2, Flu A/B, RSV, MP, Strep A), sexually transmitted infections (GBS, HPV 16/18/45, TV/MG), and monkeypox. Supporting accessories include the Pluslife Thermolyse for sample processing and portable power solutions (UPS and solar panels). Software includes mobile apps for Android/iOS and device management software. The platform delivers PCR-comparable performance with extraction-free workflows and no cold-chain requirements, enabling decentralized molecular testing in resource-limited settings.

Differentiator

Problem solved

Functional benefit

Products and services

• MiniDock Portable Molecular Diagnostic Device Palm-sized, lightweight diagnostic device with PCR-comparable accuracy that delivers results in 7–30 minutes with minimal hands-on time. Reagents require no cold-chain transport and the device includes a portable smart charging station, enabling decentralized molecular testing in resource-limited settings.
• Dock Pro 8 Molecular Diagnostic Instrument Advanced benchtop diagnostic instrument with 8 independently operating test channels for simultaneous testing. Compatible with 16+ test cards and supports LIS system integration, barcode reading, and result printing in a compact stackable design.
• MiniDock MTB Test Tuberculosis diagnostic test detecting Mycobacterium tuberculosis from sputum or tongue swabs with results in as fast as 5 minutes (up to ~30 minutes). Uses RHAM technology to deliver PCR-level performance without complex lab setup, and dual sample compatibility enables testing for patients unable to expectorate such as children, elderly, and HIV-positive individuals. First WHO-endorsed test in the new NPOC molecular TB diagnostic category.
• SARS-CoV-2/Flu A/Flu B Nucleic Acid Test Card Multiplex respiratory pathogen test for simultaneous in vitro detection of SARS-CoV-2, Influenza A, and Influenza B RNA from nasal swab samples.
• Flu A/Flu B/RSV Nucleic Acid Test Card Multiplex respiratory pathogen test for in vitro qualitative detection of Influenza A, Influenza B, and Respiratory Syncytial Virus from nasal, nasopharyngeal, or oropharyngeal swabs.
• Strep A Nucleic Acid Test Card Rapid nucleic acid test for quick, accurate detection of Group A Streptococcus from oropharyngeal swabs.
• MP (Mycoplasma pneumoniae) Nucleic Acid Test Card Rapid detection of Mycoplasma pneumoniae P1 adhesion gene from nasal or throat swabs for timely pneumonia diagnosis in children and adolescents.
• RSV Nucleic Acid Test Card Rapid molecular detection of Respiratory Syncytial Virus from nasal, nasopharyngeal, or oropharyngeal swabs.
• Monkeypox Nucleic Acid Test Card In vitro qualitative detection of Monkeypox Virus DNA in lesion exudate samples with results in 15–28 minutes.
• HPV 16/18/45 Nucleic Acid Test Card Rapid detection of high-risk HPV types 16, 18, and 45 DNA in cervical and vulvovaginal swabs for early cancer screening in women in less developed countries (developed in partnership with FIND).
• TV/MG (Trichomonas Vaginalis/Mycoplasma genitalium) Nucleic Acid Test Card In vitro qualitative detection of Trichomonas Vaginalis and Mycoplasma genitalium DNA from vaginal, cervical, male urethral swabs, and urine.
• GBS (Group B Streptococcus) Nucleic Acid Test Card Rapid in vitro detection of Group B Streptococcus DNA in vaginal swabs from pregnant women at 35–37 weeks to prevent neonatal complications.
• SARS-CoV-2 Nucleic Acid Test Card In vitro qualitative detection of SARS-CoV-2 N gene and ORF1ab gene in nasal swabs from suspected COVID-19 cases.
• Pluslife Thermolyse Sample Processing Instrument Integrated heating and mixing instrument for uniform liquid sample processing with user-friendly operation and real-time LED displays, used to prepare samples prior to running on the MiniDock or Dock Pro 8 platforms.
• 600W Pluslife Portable UPS Power Station Portable power station with 576 Wh lithium iron phosphate battery providing AC, USB, USB Type-C, and DC outputs for indoor and outdoor diagnostic deployment, especially in settings without reliable grid electricity.
• 1200W Pluslife Portable UPS Power Station Portable power station with 1152 Wh lithium iron phosphate battery providing stable AC and DC power for compatible electronic equipment in field and decentralized testing settings.
• Portable Solar Panel Lightweight, water-resistant folding solar charger with high-efficiency mono-crystalline silicon cells providing USB and DC outputs for off-grid power in remote testing environments.
• Pluslife Software & APP for Human Healthcare Mobile applications (Pluslife Android and iOS) and device management software (Pluslife PM008, PluslifePad) used to operate Pluslife diagnostic devices, manage diagnostic workflows, and review results for human healthcare.

Quantifiable outcome

• 86% sensitivity for sputum samples and 80% for tongue swabs with ~98% specificity for both sample types
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature3 records

Partnerships

Four partnerships are on record, tiered strategic and core.

• Aurum InstitutestrategicImplementation/ SI/ Consulting Partner · 23 June 2026Aurum Institute implements the 13-country Global Fund Early Adopter initiative on the ground, supporting deployment and implementation of PlusLife MiniDock MTB Test in national TB programs.
• Stop TB PartnershipcoreStrategic or Co-development Partner · 1 January 2026Stop TB Partnership supports NPOC TB testing scale-up including evidence from PlusLife MiniDock MTB Test informing WHO policy recommendations. TB REACH Wave 11 Plus invests USD 2.7 million across 18 projects in 12 countries to pilot PlusLife testing platform.
• Global Fund to Fight AIDS, Tuberculosis and MalariacoreGTM or Marketing Partner · 1 January 2025Global Fund leads Early Adopter initiative deploying PlusLife MiniDock MTB Test across 13 high-burden countries with USD 50 million commitment from CIFF. Products listed for procurement under Global Fund-supported programs.
• FINDstrategicStrategic or Co-development Partner · 1 January 2023Collaboration with FIND (Foundation for Innovative New Diagnostics) for HPV project development for the benefit of women in less developed countries. PlusLife HPV 16/18/45 product exhibits excellent clinical performance in FIND partnership.

Scale indicators8 records

Recent moves6 records

Expansion highlights7 records

Broad incumbents

• Roche Diagnostics: Roche's cobas Liat is a benchtop PCR point-of-care system used for rapid infectious disease testing in clinics and pharmacies; a much broader incumbent offering infectious disease, women's health, and STI menus overlapping with PlusLife's test card portfolio.
• Abbott: Abbott's m-PIMA HIV-1 and ID NOW molecular platforms serve global health and POC infectious disease markets; as a global incumbent, Abbott competes via portfolio breadth, established regulatory footprint, and donor relationships in overlapping LMIC procurement.
• Hologic: Hologic's Panther and Aptima molecular systems are widely used for women's health, STI, and infectious disease testing; comparable to PlusLife's HPV and STI test cards on menu and target lab customers, with significantly broader installed base.

Direct peers

• Qiagen: Qiagen's QIAstat-Dx is a cartridge-based, sample-to-answer molecular diagnostic system used for respiratory and infectious disease testing; comparable in workflow, cartridge-based test menu, and decentralized-care positioning to PlusLife's Dock Pro 8 platform.
• Molbio Diagnostics: Molbio's Truenat MTB is a battery-operated, chip-based molecular TB point-of-care platform widely deployed in primary care settings in LMICs; directly comparable to MiniDock on portability, price, and target customer (national TB programs in high-burden countries).
• Cepheid (Danaher): Cepheid's GeneXpert MTB/RIF is the dominant molecular TB diagnostic platform in high-burden countries; directly competes with PlusLife's MiniDock MTB on the same hospitals, ministries of health, and donor procurement budgets, with a much larger installed base and service network.

Regional players

• Mylab Discovery Solutions: India-based Mylab supplies molecular diagnostic kits and POC platforms for TB, HIV, and infectious diseases; comparable in price-point and target LMIC public health market, but primarily competes in India and South Asia rather than in PlusLife's 13-country Global Fund footprint.

Emerging players

• QuantuMDx: UK-based QuantuMDx is developing the Q-POC portable molecular diagnostic platform for infectious disease and antimicrobial resistance; comparable to MiniDock on portable molecular POC positioning and target global health buyer, though at an earlier commercial stage.
• SD Biosensor: South Korea-based SD Biosensor produces rapid molecular and immunodiagnostic tests (including TB) for global health markets; comparable in approach (cartridge-based, decentralized POC) and donor-channel sales to PlusLife MiniDock.
• Bioneer: South Korea-based Bioneer sells AccuPower molecular diagnostics kits and the ExiStation automated system; overlaps with PlusLife on nucleic acid amplification chemistry and infectious disease menu for global health buyers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@PluslifeBiotechCoLtd
• Facebookfacebook.com/pluslifebiotech
• LinkedInlinkedin.com/company/guangzhou-pluslife-biotech-co-ltd

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PlusLife Biotech